Shares of HENLIUS (02696) surged more than 13% during the morning trading session. At the time of writing, the stock was up 13.33% to HK$62.9, with a turnover of HK$34.75 million.
The significant price movement follows the company's announcement on June 25th that its self-developed anti-PD-1 monoclonal antibody, H drug (serplulimab), has received approval from the European Commission. The approval is for use in combination with chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic squamous non-small cell lung cancer.
This marks the fourth approved indication for the H drug in the European Union, signifying its comprehensive coverage for the first-line treatment of core lung cancer subtypes within the EU market. As a cornerstone product in HENLIUS's global strategy, the H drug is now approved for marketing in 50 countries and regions worldwide.
The company is actively advancing international clinical research and registration applications for this drug, focusing on high-incidence cancers such as lung and gastrointestinal tract tumors. Concurrently, HENLIUS is progressing with bridging studies and registration plans in key markets including the United States and Japan, aiming to solidify its global commercial foundation.
Comments